On December 14, 2023 NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported an update on its clinical pipeline (Press release, NextCure, DEC 14, 2023, View Source [SID1234638570]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NC410 (LAIR-2 fusion)
● The Phase 1b combination trial of NC410 with pembrolizumab is ongoing.
● Given evidence of clinical activity to date, additional patients are being added to the 100 mg cohort of patients with microsatellite stable/microsatellite instable-low immune checkpoint inhibitor naïve colorectal cancer without active liver metastasis.
● The combination has been safe and well tolerated to date.
● Clinical data, including results from additional patients, are expected in the first half of 2024.
LNCB74 (B7-H4 ADC) and NC762 (B7-H4 mAb)
● Due to the competitive environment and the limited activity to date, we do not plan to further develop NC762. We are prioritizing the development of LNCB74 (B7-H4 ADC), the first antibody drug conjugate (ADC) candidate from our collaboration with LegoChem Biosciences, Inc., and shifting resources from NC762 to the ADC program.
● Based on a comprehensive preclinical data package, we plan to initiate a dose range-finding toxicology study and GMP manufacturing for LNCB74 in early 2024.
NC525 (LAIR-1 mAb)
● The Phase 1a dose escalation study in subjects with acute myeloid leukemia remains ongoing with the fourth cohort now enrolled.
● Safe and well tolerated to date.
● Clinical data are expected in the first half of 2024.
● Data defining the mechanism of action were published in Journal of Clinical Investigation in November.
Business Development
● Actively seeking strategic partners to accelerate global development of programs.